Currently, the identification of new markers is of substantial importance for enabling an early diagnosis of BC.10, 11 Although a number of molecules related to BC have been described in the literature, such as forkhead box M1 (FOXM1), collagen type V alpha 2 chain (COL5A2) and N‐myc, there are still no effective molecular targets for clinical diagnosis and therapy.12, 13 Thus, more specific and sensitive biomarkers and therapeutic targets need to be identified to improve the early diagnosis and prognosis of BC patients. The gene discussed is MYCN; the disease is breast cancer.